Clinical trial
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With…
NCT03298867 · Amgen, Industry · Completed
Key facts
| NCT number | NCT03298867 |
|---|---|
| Title | Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study |
| Official title | A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease |
| Acronym | OPTIC |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thyroid Eye Disease, Graves' Orbitopathy |
| Intervention type | Biological, Other |
| Interventions | Teprotumumab, Placebo |
| Enrollment | 83 |
| Start date | Oct 4, 2017 |
| Primary completion | Feb 13, 2019 |
| Completion | Nov 30, 2020 |
| First posted | Oct 2, 2017 |
| Last update posted | Jul 11, 2024 |
| Countries | Germany, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: